{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:04:28Z","timestamp":1761843868042,"version":"build-2065373602"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.ecl.2008.11.011","type":"journal-article","created":{"date-parts":[[2009,2,13]],"date-time":"2009-02-13T08:41:02Z","timestamp":1234514462000},"page":"99-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Other Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development"],"prefix":"10.1016","volume":"38","author":[{"given":"Evan A.","family":"Stein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8934","key":"10.1016\/j.ecl.2008.11.011_bib1","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2008.11.011_bib2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2008.11.011_bib3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2008.11.011_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2008.11.011_bib5","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.ATV.15.5.678","article-title":"Reduction of LDL cholesterol by 25\u201360% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor","volume":"15","author":"Nawrocki","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ecl.2008.11.011_bib6","first-page":"253","article-title":"Lipid-altering efficacy and safety of simvastatin 80 mg\/day: worldwide long-term experience in patients with hypercholesterolemia","volume":"10","author":"Davidson","year":"2000","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.ecl.2008.11.011_bib7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ecl.2008.11.011_bib8","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1368-5031.2004.00289.x","article-title":"Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia","volume":"58","author":"Davidson","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ecl.2008.11.011_bib9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacl.2007.07.003","article-title":"Further reductions in low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum dose rosuvastatin in patients with severe hypercholesterolemia","volume":"1","author":"Stein","year":"2007","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ecl.2008.11.011_bib10","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2008.11.011_bib11","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"Incremental Decrease on End Points Through Aggressive Lipid Lowering (IDEAL) Study Group","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2008.11.011_bib12","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2008.11.011_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2008.11.011_bib14","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2008.11.011_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2007.08.024","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: executive summary","volume":"194","author":"Ian Graham","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ecl.2008.11.011_bib16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.amjcard.2005.04.019","article-title":"Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations","volume":"96","author":"Davidson","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ecl.2008.11.011_bib17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ecl.2008.11.011_bib18","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.amjcard.2007.09.099","article-title":"Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins: a randomized, double-blind, double-dummy trial","volume":"101","author":"Stein","year":"2008","journal-title":"Am J Cardiol"},{"year":"2008","series-title":"Antisense drug technology. Principles, strategies and applications","key":"10.1016\/j.ecl.2008.11.011_bib19"},{"key":"10.1016\/j.ecl.2008.11.011_bib20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1194\/jlr.M400492-JLR200","article-title":"An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis","volume":"46","author":"Crooke","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ecl.2008.11.011_bib21","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","article-title":"Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression","volume":"268","author":"Monia","year":"1993","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ecl.2008.11.011_bib22","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","article-title":"Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B","volume":"114","author":"Kastelein","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2008.11.011_bib23","unstructured":"Isis reports new data for mipomersen in routine high cholesterol patients and provides cumulative safety summary [press release]. Newswire. November 13, 2007. Accessed February 12, 2008."},{"key":"10.1016\/j.ecl.2008.11.011_bib24","unstructured":"Kastelein J, Trip M, Davidson M, et\u00a0al. Safety and activity of ISIS 301012 in heterozygous familial hypercholesterolemia [abstract 341]. Presented at Drugs Affecting Lipid Metabolism. Journal of Clinical Lipidology 2007;1(5):475."},{"key":"10.1016\/j.ecl.2008.11.011_bib25","unstructured":"Stein EA. High LDL-C on three drugs. Presented at ACC National Meeting. New Orleans, March 26, 2007."},{"key":"10.1016\/j.ecl.2008.11.011_bib26","unstructured":"Princeton, N.J. and CARLSBAD, Calif., May 9, 2007\/PRNewswire-FirstCall via COMTEX News Network\/\u2013Bristol-Myers Squibb Company (NYSE: BMY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS). Accessed May 20, 2008."},{"key":"10.1016\/j.ecl.2008.11.011_bib27","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1126\/science.1439810","article-title":"Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia","volume":"258","author":"Wetterau","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.ecl.2008.11.011_bib28","unstructured":"Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, editors. The metabolic and molecular bases of inherited disease. 8th Edition. New York: McGraw-Hill Professional; 2000."},{"key":"10.1016\/j.ecl.2008.11.011_bib29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jama.1993.03510070087042","article-title":"Abetalipoproteinemia: new insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease","volume":"270","author":"Rader","year":"1993","journal-title":"JAMA"},{"issue":"18 Suppl 1","key":"10.1016\/j.ecl.2008.11.011_bib30","article-title":"Effect of BAY 13-9952, a microsomal triglyceride transfer protein inhibitor on lipids and lipoproteins in dyslipoproteinemic patients [abstract 1342]","volume":"100","author":"Stein","year":"1999","journal-title":"Circulation"},{"issue":"18, Suppl II","key":"10.1016\/j.ecl.2008.11.011_bib31","first-page":"II-601","article-title":"Inhibition of post-prandial fat absorption with the MTP inhibitor BAY 13-9952","volume":"102","author":"Stein EA","year":"2000","journal-title":"Circulation"},{"issue":"18 Suppl 1","key":"10.1016\/j.ecl.2008.11.011_bib32","article-title":"BAY 13-9952, an inhibitor of the microsomal triglyceride transfer protein (MTP), dose-dependently blocks the formation of atherosclerotic plaques and renders them more stable in apoE knockout mice [abstract 1343]","volume":"100","author":"Zaiss","year":"1999","journal-title":"Circulation"},{"issue":"Suppl","key":"10.1016\/j.ecl.2008.11.011_bib33","article-title":"BAY 13-9952 (implitapide): pharmacodynamic effects of a new and highly active inhibitor of the microsomal-triglyceride-transfer-protein (MTP) [abstract TuP9:W16]","volume":"21","author":"Bischoff","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ecl.2008.11.011_bib34","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1126\/science.282.5389.751","article-title":"An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits","volume":"282","author":"Wetterau","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ecl.2008.11.011_bib35","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1194\/jlr.M300094-JLR200","article-title":"CP-346086: an MTP inhibitor that lowers plasma total, VLDL, and LDL cholesterol and triglycerides by up to 70% in experimental animals and in humans","volume":"44","author":"Chandler","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ecl.2008.11.011_bib36","unstructured":"Farnier M, Stein E, Megnien S, et\u00a0al. Efficacy and safety of implitapide, a microsomal triglyceride transfer protein inhibitor in patients with primary hypercholesterolemia. Abstract Book of the XIV International Symposium on Drugs Affecting Lipid Metabolism in New York, September 9\u201312, 2001:46."},{"key":"10.1016\/j.ecl.2008.11.011_bib37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0002-9149(97)00298-1","article-title":"The rule of 5 and the rule of 7 in lipid-lowering by statin drugs","volume":"80","author":"Roberts","year":"1997","journal-title":"Am J\u00a0Cardiol"},{"key":"10.1016\/j.ecl.2008.11.011_bib39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"year":"2007","series-title":"Common stock registration statement. AMENDMENT NO. 3 to FORM S-1; May 25, 2007","key":"10.1016\/j.ecl.2008.11.011_bib40"},{"key":"10.1016\/j.ecl.2008.11.011_bib41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.ecl.2008.11.011_bib43","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1172\/JCI104323","article-title":"Effects of triparanol (mer-29) on cholesterol biosynthesis and on blood sterol levels in man","volume":"40","author":"Steinberg","year":"1961","journal-title":"J Clin Invest"},{"journal-title":"Time Magazine.","article-title":"Triparanol side effects","year":"1964","key":"10.1016\/j.ecl.2008.11.011_bib44"},{"key":"10.1016\/j.ecl.2008.11.011_bib45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.ecl.2008.11.011_bib46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0014-2999(03)01549-8","article-title":"Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia","volume":"466","author":"Amano","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ecl.2008.11.011_bib47","doi-asserted-by":"crossref","first-page":"11705","DOI":"10.1016\/S0021-9258(19)49754-8","article-title":"Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo","volume":"267","author":"Baxter","year":"1992","journal-title":"J Biol Chem"},{"issue":"33","key":"10.1016\/j.ecl.2008.11.011_bib48","doi-asserted-by":"crossref","first-page":"24832","DOI":"10.1016\/S0021-9258(19)74540-2","article-title":"Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo","volume":"268","author":"Ciosek","year":"1993","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.ecl.2008.11.011_bib49","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1021\/np50101a009","article-title":"Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase","volume":"56","author":"Dufresne","year":"1993","journal-title":"J Nat Prod"},{"key":"10.1016\/j.ecl.2008.11.011_bib50","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0022-3565(24)36653-4","article-title":"RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase","volume":"281","author":"Amin","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ecl.2008.11.011_bib51","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S0022-2275(20)32020-4","article-title":"Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors","volume":"41","author":"Hiyoshi","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ecl.2008.11.011_bib52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjp.0703545","article-title":"YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species","volume":"131","author":"Ugawa","year":"2000","journal-title":"Br J Pharmacol"},{"issue":"12","key":"10.1016\/j.ecl.2008.11.011_bib53","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.7164\/antibiotics.54.1025","article-title":"CJ-13981 and CJ-13982, new squalene synthase inhibitors","volume":"54","author":"Watanabe","year":"2001","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ecl.2008.11.011_bib54","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1073\/pnas.87.22.8931","article-title":"Lovastatin decreases coenzyme Q levels in humans","volume":"87","author":"Folkers","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"33","key":"10.1016\/j.ecl.2008.11.011_bib55","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/j.1552-4604.1993.tb03948.x","article-title":"Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study","author":"Ghirlanda","year":"1993","journal-title":"J\u00a0Clin Pharmacol"},{"year":"1990","author":"US Patent 4 933 165","key":"10.1016\/j.ecl.2008.11.011_bib56"},{"key":"10.1016\/j.ecl.2008.11.011_bib57","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy","volume":"49","author":"Marcoff","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2008.11.011_bib58","doi-asserted-by":"crossref","first-page":"9197","DOI":"10.1074\/jbc.272.14.9197","article-title":"Farnesol- derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol","volume":"272","author":"Bostedor","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ecl.2008.11.011_bib59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1006\/abbi.1998.0704","article-title":"Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A","volume":"355","author":"Vaidya","year":"1998","journal-title":"Arch Biochem Biophys"},{"issue":"18 Suppl","key":"10.1016\/j.ecl.2008.11.011_bib60","first-page":"II-288","article-title":"TAK-475, a squalene synthase inhibitor improves lipid profle in hyperlipidemic subjects [abstract 1493]","volume":"114","author":"Piper","year":"2006","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2008.11.011_bib61","first-page":"S37","article-title":"TAK-475, a squalene synthase inhibitor, coadministered with atorvastatin: a pharmacokinetic study [abstract]. American Society for Clinical Pharmacology and Therapeutics Annual Meeting March 21\u201324, 2007 Anaheim, CA (PI-75)","volume":"91","author":"Piper","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ecl.2008.11.011_bib64","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.ecl.2008.11.011_bib65","doi-asserted-by":"crossref","first-page":"20799","DOI":"10.1074\/jbc.C700095200","article-title":"Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells","volume":"282","author":"McNutt","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ecl.2008.11.011_bib66","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1373\/clinchem.2007.091280","article-title":"Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol","volume":"53","author":"Alborn","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.ecl.2008.11.011_bib67","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2008.11.011_bib68","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ecl.2008.11.011_bib69","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice","volume":"48","author":"Graham","year":"2007","journal-title":"J\u00a0Lipid Res"},{"year":"2008","series-title":"Bristol-Myers Squibb selects Isis drug targeting PCSK9 as development candidate for prevention and treatment of cardiovascular disease","key":"10.1016\/j.ecl.2008.11.011_bib70"},{"key":"10.1016\/j.ecl.2008.11.011_bib72","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ecl.2008.11.011_bib73","unstructured":"AstraZeneca AZD4121. Available at: http:\/\/www.myfatdog.com\/phase_ii_pipeline. Accessed August 3, 2008."},{"issue":"2","key":"10.1016\/j.ecl.2008.11.011_bib75","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1074\/jbc.M406309200","article-title":"Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor Ezetimibe in the enterocyte brush border membrane","volume":"280","author":"Kramer","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ecl.2008.11.011_bib76","unstructured":"Chew P. Presented at Cowen - 28th Annual Health Care Conference. Boston, March 18, 2008. Available at: http:\/\/en.sanofi-aventis.com\/Default.aspx. Accessed January 16, 2009."}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985290800087X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985290800087X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:32:41Z","timestamp":1760175161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985290800087X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S088985290800087X"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2008.11.011","relation":{},"ISSN":["0889-8529"],"issn-type":[{"type":"print","value":"0889-8529"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Other Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2008.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}